1. Home
  2. DEO vs ZTS Comparison

DEO vs ZTS Comparison

Compare DEO & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diageo plc

DEO

Diageo plc

HOLD

Current Price

$86.99

Market Cap

47.6B

ML Signal

HOLD

Logo Zoetis Inc.

ZTS

Zoetis Inc.

HOLD

Current Price

$125.99

Market Cap

53.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEO
ZTS
Founded
1886
1952
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.6B
53.9B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DEO
ZTS
Price
$86.99
$125.99
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$109.00
$174.60
AVG Volume (30 Days)
1.7M
6.0M
Earning Date
02-03-2026
02-12-2026
Dividend Yield
4.72%
1.69%
EPS Growth
N/A
11.64
EPS
1.06
5.94
Revenue
$20,245,000,000.00
$9,397,000,000.00
Revenue This Year
$2.58
$3.04
Revenue Next Year
$3.33
$4.98
P/E Ratio
$81.62
$21.19
Revenue Growth
N/A
2.68
52 Week Low
$85.12
$115.25
52 Week High
$127.33
$177.40

Technical Indicators

Market Signals
Indicator
DEO
ZTS
Relative Strength Index (RSI) 44.46 55.97
Support Level $85.48 $125.45
Resistance Level $86.94 $127.60
Average True Range (ATR) 1.18 2.46
MACD 0.09 0.89
Stochastic Oscillator 39.02 83.71

Price Performance

Historical Comparison
DEO
ZTS

About DEO Diageo plc

Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.

About ZTS Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Share on Social Networks: